Cargando…

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera

Detalles Bibliográficos
Autores principales:	Barbui, Tiziano, De Stefano, Valerio, Ghirardi, Arianna, Masciulli, Arianna, Finazzi, Guido, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255832/ https://www.ncbi.nlm.nih.gov/pubmed/30478311 http://dx.doi.org/10.1038/s41408-018-0161-9

Ejemplares similares

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
por: Ghirardi, Arianna, et al.
Publicado: (2018)

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
por: Ferrari, Alberto, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
por: Carobbio, Alessandra, et al.
Publicado: (2022)

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
por: De Stefano, Valerio, et al.
Publicado: (2018)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis?
por: Teofili, Luciana, et al.
Publicado: (2018)

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
por: Marchioli, Roberto, et al.
Publicado: (2011)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
por: Tefferi, Ayalew, et al.
Publicado: (2021)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

The development of polycythemia vera after phlebotomy treatment for hereditary haemochromatosis
por: van Bommel, Erik JM, et al.
Publicado: (2021)

Cerebral venous sinus thrombosis in polycythemia vera patients with JAK2V617F mutation
por: Shen, Hui-Xin, et al.
Publicado: (2021)

Optimized and Personalized Phlebotomy Schedules for Patients Suffering From Polycythemia Vera
por: Lilienthal, Patrick, et al.
Publicado: (2020)

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera
por: Nguyen, Eliane, et al.
Publicado: (2021)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
por: Alvarez-Larrán, Alberto, et al.
Publicado: (2020)

PB2202: NOVEL PREDICTORS FOR VENOUS AND ARTERIAL THROMBOSIS IN POLYCYTHEMIA VERA
por: Ivanović, Jelena, et al.
Publicado: (2023)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
por: Triguero, Ana, et al.
Publicado: (2022)

P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
por: Kuykendall, Andrew T.
Publicado: (2023)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
por: De Stefano, Valerio, et al.
Publicado: (2018)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

Oral hyperpigmentation associated with hydroxyurea in a patient with polycythemia vera: A case report
por: Alshammasi, Baneen, et al.
Publicado: (2020)

Correction to: Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
por: Kuykendall, Andrew T.
Publicado: (2023)

Partial Status Epilepticus in Cerebral Venous Sinus Thrombosis, Initial Manifestation of Polycythemia Vera
por: Eliaçik, Sinan, et al.
Publicado: (2019)

Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera
por: Martins De Oliveira Filho, Cilomar, et al.
Publicado: (2022)

Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
por: Barbui, Tiziano, et al.
Publicado: (2019)

Myeloid Sarcoma Developing in Prexisting Hydroxyurea-Induced Leg Ulcer in a Polycythemia Vera Patient
por: Nafil, Hatim, et al.
Publicado: (2013)

Pulmonary vein thrombosis in a patient with polycythemia vera
por: Bhardwaj, Bhaskar, et al.
Publicado: (2016)

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
por: Tefferi, A, et al.
Publicado: (2013)

Prefibrotic myelofibrosis: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
por: Cerquozzi, S., et al.
Publicado: (2017)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e9cb1bp61i4mnapjr82ufe39sr